
Aquestive Therapeutics Broadens Patent Estate for Anaphylm™
New patents extend protection for Anaphylm™ into 2037 Anaphylm (dibutepinephrine) Sublingual Film, if approved by the FDA, will be the first and only oral medication for the rescue treatment of severe allergic reactions, including anaphylaxis WARREN, N.J., …